Search for: "Green v. Pfizer Inc"
Results 41 - 53
of 53
Sorted by Relevance
|
Sort by Date
11 Jul 2008, 4:30 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: ACTA continues to be discussed and debated: (Michael Geist), (Intellectual Property Watch), (Public Knowledge), (Techdirt), (Managing Intellectual Property), (Public Knowledge), (Public Knowledge), (Public Knowledge), Apotex challenge to Acular LS patent barred by res judicata: Roche Palo Alto & Allergan v Apotex:… [read post]
5 Jul 2008, 11:05 am
: (Intellectual Property Watch), Why compulsory licenses are bad: a look at the sausage making process: (Techdirt) More on ACTA: (LawFont.com) Global - Trade Marks / Domain Names / Brands Brand Finance 500: the annual report on the world’s most valuable brands: (IP finance), Gretchen Olive’s ‘10 steps to an effective domain name policy’: (IPwar’s), ICANN approves GNSO proposals imposing financial penalty on registrars who engage in excessive domain… [read post]
28 Mar 2008, 6:00 am
: (Afro-IP),If education and pricing policy fail, says Adobe in Nigeria, we can still sue: (Afro-IP),South African arm of Chrysler objects to advertisement by Indian vehicle maker Mahindra and Mahindra that uses the term "jeep": (Afro-IP), (Spicy IP),Kenya’s call for anti-counterfeit legislation… amongst other changes: (Afro-IP),Kenya: Shared computer use raises privacy, confidentiality issues: (Afro-IP)AustraliaChanges to grace period for trade mark renewal:… [read post]
9 Mar 2010, 12:20 am
Though the justices almost never reveal their reasons for recusal, this one is almost certainly based on Roberts' stock ownership in Pfizer, which also became an issue in last year's landmark pre-emption case Wyeth v. [read post]
2 May 2008, 7:00 am
: (Patent Baristas), US: How to avoid a permanent injunction: the lessons of Amgen v Hoffman-LaRoche: (Patent Docs), US: Jarvik Heart’s PTE request based on PMA shell/module submission dates flatlines; ruling on initiation of PTE ‘review period’ mirrors FDA policy for ‘fast track’ products: (FDA Law Blog) Pharma & Biotech - Products Kytril (Granisetron) – Exclusivity ‘parking’ still… [read post]
8 Jul 2012, 10:58 am
Green, D. [read post]
16 Aug 2009, 9:51 pm
In reliance of Black & Decker, Inc. v Robert Bosch Tool Corp (2008) Microsoft argued that the objective prong of the willfulness analysis is satisfied only if a defendant fails to present valid defences during the proceedings. [read post]
10 Jan 2022, 4:01 pm
The incident followed the publication of a peer-review article that questioned the integrity and regulatory oversight issues surrounding Pfizer’s phase III Covid-19 vaccine trial. [read post]
5 Sep 2008, 11:01 pm
& Ors v Deisel Spa and Case C-302/08 Zino Davidoff SA v Bendesfinanzdirektion Sudost: (Class 46), EPO Boards of Appeal finds that when a fax is transmitted and an ‘OK’ is noted by the sender, this is evidence that the transmission was successful: (IPKat), Professor Hugenholtz slams European Commission for ignoring evidence on copyright extension: (Techdirt) Germany Federal Patent Court publishes guidelines on colour trade mark Signal Yellow:… [read post]
18 Jul 2008, 8:34 am
: (Patent Circle), Tanzania to conduct study on impact of counterfeit medicines: (Afro-IP), US: New rules on generic biological medicines under US Congressional debate: (Intellectual Property Watch), Pharma & Biotech - Products Acular (Ketorolac) – US: CAFC rules against Apotex reverse doctrine of equivalents: Roche Palo Alto & Allergan, Inc v Apotex: (Patent Circle), Carbatrol (Carbamazapine) – US: Federal judge allows Corepharma to seek DJ… [read post]
9 May 2007, 1:34 pm
Stephenson v. [read post]
13 Jul 2021, 10:58 am
In the United States (US), as for most developed countries,[6] trade policy and IP standards have consistently been linked, a pattern which can (at least partially) be traced back to extensive lobbying by senior management at US-based technology and pharmaceutical firms.[7] For example, since at least the 1980s, Pfizer Inc. has been involved in mobilizing other US firms and stakeholders to lobby US policymakers on the issue of international IP protection. [read post]
3 Jan 2023, 1:47 pm
The directors’ and officers’ liability environment is always changing, but 2022 was a particularly eventful year, with important consequences for the D&O insurance marketplace. [read post]
